Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5

BACKGROUND: High-risk medulloblastoma is defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Dufour, Christelle, Foulon, Stephanie, Geoffray, Anne, Masliah-Planchon, Julien, Figarella-Branger, Dominique, Bernier-Chastagner, Valerie, Padovani, Laetitia, Guerrini-Rousseau, Léa, Faure-Conter, Cecile, Icher, Celine, Bertozzi, Anne-Isabelle, Leblond, Pierre, Akbaraly, Tasnime, Bourdeaut, Franck, André, Nicolas, Chappé, Celine, Schneider, Pascale, De Carli, Emilie, Chastagner, Pascal, Berger, Claire, Lejeune, Julien, Soler, Christine, Entz-Werlé, Natacha, Delisle, Marie-Bernadette
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2020
Schlagworte:
Pediatric Neuro-Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248855/
https://ncbi.nlm.nih.gov/pubmed/33377141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa301
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge